MDMA and methamphetamine: Some paradoxical negative and positive mood changes in an acute dose laboratory study

Psychopharmacology

Volumn 215, Issue 3, 2011, Pages 527-536

  Parrott, Andrew C ^a,c   Gibbs, Amy ^a   Scholey, Andrew B ^a   King, Rebecca ^a   Owens, Katherine ^a   Swann, Phil ^a   Ogden, Ed ^b   Stough, Con ^a  

^a SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^b DEPARTMENT OF PRIMARY INDUSTRIES   (Australia)

^c SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Dopamine; Ecstasy; Environment; MDMA; Methamphetamine; Mood; PANAS; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; METHAMPHETAMINE;

ADULT; ARTICLE; DRUG DOSE; ENVIRONMENTAL FACTOR; FEMALE; GENDER; HUMAN; HUMAN EXPERIMENT; LABORATORY; MALE; MOOD; MOOD CHANGE; NEGATIVE MOOD; NEUROENDOCRINOLOGY; NORMAL HUMAN; POSITIVE MOOD; PRIORITY JOURNAL; SOCIAL ASPECT;

EID: 80052329709     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2184-9     Document Type: Article

References (59)

1. Baylen CA, Rosenberg N (2006) A review of the acute subjective effects of MDMA/ecstasy. Addiction 101: 933-994
2. Bedi G, de Wit H (2011). Individual differences in acute responses to MDMA in humans: effects of sex and past ecstasy use. Open Addiction Journal (in press)
3. Bedi G, Phan KL, Angstadt M, de Wit H (2009) Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology 207: 73-83
4. Bedi G, Hyman D, de Wit H (2010) Is ecstasy an empathogen? Effects of 3, 4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry 68: 1134-1140
5. Cadet JL, Krasnova IN, Jayanthi S, Lyles J (2007) Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res 11: 183-202
6. Cami J, Farré M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R (2000) Human pharmacology of 3, 4- methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. J Clin Psychopharmacol 20: 455-466 (Pubitemid 30463762)
7. Clemens KJ, McGregor IS, Hunt GE, Cornish JL (2007) MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research. Drug Alcohol Rev 26: 9-15
8. Cohen RS (1998) The love drug: marching to the beat of ecstasy. Haworth Medical Press, New York State
9. Comer SD, Hart CL, Ward AS, Haney M, Foltin RW, Fischman MW (2001) Effects of repeated oral methamphetamine administration in humans. Psychopharmacology 155: 397-404 (Pubitemid 32523110)
10. Cruickshank CC, Dyer KR (2009) A review of the clinical pharmacology of methamphetamine. Addiction 104: 1085-1099
11. Davison D, Parrott AC (1997) Ecstasy in recreational users: selfreported psychological and physiological effects. Hum Psychopharmacol 12: 91-97
12. Degenhardt L, Hall W (2009). The health and psychological effects of "ecstasy" (MDMA) use. NDARC monograph, no. 62. University of New South Wales, Australia
13. Dumont GJ, Verkes RJ (2006) A review of acute effects of 3, 4- methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol 20: 176-187
14. Dumont GJ, Sweep FC, van der Steen R, Hermsen R, Donders AR, Touw DJ, van Gerven JM, Buitelaar JK, Verkes RJ (2009) Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3, 4-methylenedioxymethamphetamine) administration. Soc Neurosci 4: 359-366
15. Dumont GJ, Schoemaker RC, Touw DJ, Sweep FC, Buitelaar JK, van Gerven JM, Verkes RJ (2010) Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers. J Psychopharmacol 24: 155-164
16. Farré M, de la Torre R, Mathúna BO, Roset PN, Peiró AM, Torrens M, Ortuño J, Pujadas M, Camí J (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology 173: 364-375 (Pubitemid 38703810)
17. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3, 4- methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55: 463-508 (Pubitemid 37013213)
18. Greer G, Tolbert R (1990). The therapeutic use of MDMA. The clinical, pharmacological and neurotoxicological effects of the drug MDMA. Peroutka SJ (ed.). Kluwer, New York
19. Greer G, Tolbert R (1986). Subjective reports of the effects of MDMA in a clinical setting. J Psychoact Drugs 18: 319-327 (Pubitemid 17231263)
20. Hart CL, Ward AS, Haney M, Foltin RW, Fischman MW (2001) Methamphetamine self-administration by humans. Psychopharmacology 157: 75-81 (Pubitemid 32758962)
21. Hart CL, Gunderson EW, Perez A, Kirkpatrick MG, Thurmond A, Comer SD et al (2008) Acute physiological and behavioral effects of intranasal methamphetamine in humans. Neuropsychopharmacology 33: 1847-1855 (Pubitemid 351832594)
22. Hernández-López C, Farré M, Roset PN, Menoyo E, Pizarro N, Ortuño J, Torrens M, Camí J, de La Torre R (2002) 3, 4- Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther 300: 236-244 (Pubitemid 34028533)
23. Irvine RJ, Keane M, Felgate P, McCann UD, Callaghan PD, White JM (2006) Plasma drug concentrations and physiological measures in 'dance party' participants. Neuropsychopharmacology 31: 424-430 (Pubitemid 43113406)
24. Iversen L (2006) Speed, ecstasy, ritalin: the science of the amphetamines. Oxford University Press, Oxford
25. Johanson CE, Kilbey M, Gatchalian K, Tancer M (2006) Discriminative stimulus effects of 3, 4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among damphetamine, meta-chlorophenylpiperazine and placebo. Drug Alcohol Depend 81: 27-36 (Pubitemid 41682476)
26. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA (2008) Physiological and subjective responses to controlled oral 3, 4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol 28: 432-440
27. Liechti ME, Gamma A, Vollenweider FX (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology 154: 161-168 (Pubitemid 32186501)
28. Lynch WJ, Roth ME, Carroll ME (2002) Biological basis of sex differences in drug abuse: pre-clinical and clinical studies. Psychopharmacology 164: 121-137 (Pubitemid 36015575)
29. Mter Bogt TF, Engels RC (2005) "Partying" hard: party style, motives for and effects of MDMA use at rave parties. Subst Use Misuse 40: 1479-1502
30. McCardle K, Luebbers S, Carter JD, Croft RJ, Stough C (2004) Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology 173: 434-439 (Pubitemid 38703819)
31. McGregor IS, Callaghan PD, Hunt GE (2008) From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use? Br J Pharmacol 154: 358-368 (Pubitemid 351670596)
32. Mendelson J, Uemura N, Harris D, Nath RP, Fernandez E, Jacob P, Everhart ET, Jones RT (2006) Human pharmacology of the methamphetamine stereoisomers. Clin Pharmacol Ther 80: 403-420 (Pubitemid 44479752)
33. Murphy PN, Wareing M, Fisk JE, Montgomery C (2009) Executive working memory deficits in abstinent ecstasy/MDMA users: a critical review. Neuropsychobiology 60: 159-175
34. Papafotiou K, Carter JD, Stough C (2005) The relationship between performance on the standardised field sobriety tests, driving performance and the level of Delta9-tetrahydrocannabinol (THC) in blood. Forensic Sci Int 155: 172-178 (Pubitemid 41454954)
35. Parrott AC (1994) Individual differences in stress and arousal during cigarette smoking. Psychopharmacology 115: 389-396 (Pubitemid 24217100)
36. Parrott AC (1999) Does cigarette smoking cause stress? Am Psychol 54: 817-820
37. Parrott AC (2001) Human psychopharmacology of Ecstasy (MDMA): a review of fifteen years of empirical research. Hum Psychopharmacol 16: 557-577 (Pubitemid 34040989)
38. Parrott AC (2002) Recreational MDMA (Ecstasy), the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 71: 837-844 (Pubitemid 34219233)
39. Parrott AC (2004a) Is Ecstasy MDMA ? A review of the proportion of ecstasy tablets containing MDMA, dosage levels, and the changing perceptions of purity. Psychopharmacology 173: 234-241 (Pubitemid 38703796)
40. Parrott AC (2004b) MDMA (3, 4-methylenedioxymethamphetamine) or Ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 50: 329-335 (Pubitemid 39482673)
41. Parrott AC (2005) Chronic tolerance to recreational MDMA (3, 4- methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol 19: 71-83
42. Parrott AC (2006) MDMA in humans: factors which affect the neuropsychobiological profiles of recreational Ecstasy users, the integrative role of bio-energetic stress. J Psychopharmacol 20: 147-163
43. Parrott AC (2009) Cortisol and MDMA: neurohormonal aspects of bioenergetic stress in Ecstasy users. Neuropsychobiology 60: 148-158
44. Parrott AC (2010) Conscious awareness versus optimistic beliefs in recreational Ecstasy/MDMA users. In: Perry E, Collerton D, LeBeau F, Ashton HE (eds) New horizons in the neuroscience of consciousness. John Benjamins Publishers, Amsterdam
45. Parrott AC, Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition; before, during, and after a Saturday night dance. Psychopharmacology 139: 261-268 (Pubitemid 28439526)
46. Parrott AC, Lock J, Conner AC, Kissling C, Thome J (2008) Dance clubbing on-MDMA and during abstinence from MDMA: prospective neuroendocrine and psychobiological changes. Neuropsychobiology 57: 165-180
47. Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3, 4- methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1: 273-277 (Pubitemid 19126146)
48. Scholey AB, Parrott AC, Buchanan T, Heffernan T, Ling J, Rodgers J (2004) Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a www study. Addict Behav 29: 743-752 (Pubitemid 38591581)
49. Scholey AB, Owen L, Gates J, Rodgers J, Buchanan T, Ling J, Heffernan T, Swan P, Stough C, Parrott AC (2010) Hair MDMA samples are consistent with reported Ecstasy use: findings from a study investigating effects of Ecstasy on mood and memory. Neuropsychobiology 63: 15-21
50. Silber BY, Croft RJ, Papafotiou K, Stough C (2006) The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance. Psychopharmacology 187(1): 54-169
51. Solowij N, Hall W, Lee N (1992) Recreational MDMA use in Sydney: a profile of ecstasy users and their experiences with the drug. Br J Addict 87: 1161-1172
52. Tancer ME, Johanson CE (2001) The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 65: 97-101 (Pubitemid 33063665)
53. Tancer ME, Johanson CE (2003) Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend 72: 33-44
54. Tancer M, Johanson CE (2007) The effects of fluoxetine on the subjective and physiological effects of 3, 4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 189: 565-573 (Pubitemid 44791225)
55. Topp L, Hando J, Dillon P, Roche A, Solowij N (1999) Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55: 105-115 (Pubitemid 29222009)
56. Verheyden SL, Henry JA, Curran HV (2003) Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users. Hum Psychopharmacol 18: 507-517 (Pubitemid 37279232)
57. Watson D, Clark LA, Tellegen A (1988) Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54: 1063-1070
58. White TL, Lott DC, de Wit H (2006) Personality and the subjective effects of acute amphetamine in healthy volunteers. Neuropsychopharmacology 31: 1064-1074
59. Yacoubian GS, Boyle C, Harding CA, Loftus EA (2003) It's a rave new world: estimating the prevalence and perceived harm of ecstasy and other drug use among club rave attendees. J Drug Educ 33: 187-196 (Pubitemid 36935940)